文献速递免疫规划卫生政策与健康促进

大学适龄青年B群脑膜炎球菌疫苗接种的成本效果分析

Cost Effectiveness of Meningococcal Serogroup B Vaccination in College-Aged Young Adults.
PubMed 文献 · Am J Prev Med · 2018-12-17

本研究评估美国中型四年制大学新生普遍接种B群脑膜炎球菌疫苗的成本效果,采用健康部门与社会视角,与疫情应对策略比较。

要点

  • 大学入学时普遍接种B群脑膜炎球菌疫苗不具成本效果。
  • 仅在疫苗系列价格低于65美元等极有利条件下才可能具成本效果。

核心结论

  • 大学入学时普遍接种B群脑膜炎球菌疫苗不具成本效果。
  • B群脑膜炎奈瑟菌感染罕见是导致普遍接种缺乏成本效果的原因。

研究设计与样本

  • 基于美国中型四年制大学背景,从健康部门和社会视角比较普遍接种与不接种加疫情应对的成本与收益。
  • 成本(2015年美元)和收益按3%贴现,数据来自已发表文献。
  • 进行单因素和多因素概率敏感性分析,包括疫苗品种变化,并测试参数极端值以识别有利条件。

主要发现

  • 多因素概率敏感性分析显示,在每质量调整生命年低于1500万美元的支付意愿下,普遍接种不是优选策略。
  • 在极有利模型下,疫苗系列价格低于65美元时普遍接种才具成本效果。

关键数值与推荐

  • 支付意愿阈值为每质量调整生命年15万美元。
  • 极有利条件下成本效果的价格阈值:疫苗系列价格低于65美元。

临床怎么用

  • 在决策大学新生普遍接种B群脑膜炎球菌疫苗时,应参考成本效果证据,优先考虑疫情应对策略。
  • 若疫苗系列价格显著降低(如低于65美元),可重新评估普遍接种的成本效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Neisseria meningitidis serogroup B is the most common form of meningococcal infection in young adults in the U.S. Vaccines have recently become available, but it is not clear that the benefits outweigh the costs. The purpose of this study was to assess cost effectiveness and determine potentially favorable conditions for universal vaccination. METHODS: Costs and benefits of universal vaccination at college entry versus no universal vaccination with an outbreak response were estimated in 2018 in the context of a mid-sized U.S.-based 4-year college from both a health sector and a societal perspective. Probability, cost, and utility data were obtained from the published literature. Costs (2015 U.S.$) and benefits were discounted at 3%. One-way and multivariable probabilistic sensitivity analyses were performed including variations in the specific vaccine used. Further testing of the model's parameters at extremes was used to identify favorable conditions for universal vaccination. RESULTS: The incremental cost per quality-adjusted life year gained with universal vaccination was $13.9 million under the health sector perspective and $13.8 million under the societal perspective, each perspective was compared with a willingness-to-pay threshold of $150,000 per quality-adjusted life year. Multivariable probabilistic sensitivity analysis showed that universal vaccination was not the preferred strategy for <$15 million per quality-adjusted life year. Under an extremely favorable model, a universal vaccination strategy became cost effective for vaccine series costing <$65. CONCLUSIONS: This study demonstrates that universal vaccination at college entry is not cost effective. The rarity of N. meningitidis serogroup B contributes to the lack of cost effectiveness for universal vaccination.

来源:Am J Prev Med,查看原文。版权归原作者所有。

引用

  1. Leeds IL, Namasivayam V, Bamogo A, et al. Cost Effectiveness of Meningococcal Serogroup B Vaccination in College-Aged Young Adults. Am J Prev Med. 2018. PMID: 30573332. doi:10.1016/j.amepre.2018.09.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。